Skip to main content

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

Completed · Not applicable · NCT03795298

Conditions: Atrial Fibrillation

At a glance

Research payments reported, 2025
$248,290
U.S. investigators named
53
Sites paid
52
Planned or actual enrollment
1,600

About the trial

Sponsor
Boston Scientific Corporation
Tested
WATCHMAN FLX Implant (device), Market-approved OAC (drug)
Dates
Started 2019-05-20; completion 2024-07-24
Results posted
Yes

The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation.

From ClinicalTrials.gov, last updated 2025-09-18. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $248,290 in research payments for this study in 2025 (101 payments).

Products named: Watchman Access System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.